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ultimodality Noninvasive
maging Demonstrates In Vivo Cardiac
egeneration After Mesenchymal Stem Cell Therapy
uciano C. Amado, MD,*† Karl H. Schuleri, MD,*† Anastasios P. Saliaris, MD,*†
ndrew J. Boyle, MBBS, PHD,*† Robert Helm, MD,* Behzad Oskouei, MD,*† Marco Centola, MD,*†
irginia Eneboe, VT,*† Randell Young, MVD,‡ Joao A. C. Lima, MD,* Albert C. Lardo, PHD,*
lan W. Heldman, MD,*† Joshua M. Hare, MD*†
altimore, Maryland
OBJECTIVES The purpose of this study was to test the hypothesis, with noninvasive multimodality imaging,
that allogeneic mesenchymal stem cells (MSCs) produce and/or stimulate active cardiac
regeneration in vivo after myocardial infarction (MI).
BACKGROUND Although intramyocardial injection of allogeneic MSCs improves global cardiac function
after MI, the mechanism(s) underlying this phenomenon are incompletely understood.
METHODS We employed magnetic resonance imaging (MRI) and multi-detector computed tomography
(MDCT) imaging in MSC-treated pigs (n  10) and control subjects (n  12) serially for
a 2-month period after anterior MI. A sub-endocardial rim of tissue, demonstrated with
MDCT, was assessed for regional contraction with MRI tagging. Rim thickness was also
measured on gross pathological specimens, to confirm the findings of the MDCT imaging,
and the size of cardiomyocytes was measured in the sub-endocardial rim and the non-infarct
zone.
RESULTS Multi-detector computed tomography demonstrated increasing thickness of sub-endocardial
viable myocardium in the infarct zone in MSC-treated animals (1.0 0.2 mm to 2.0 0.3 mm,
1 and 8 weeks after MI, respectively, p  0.028, n  4) and a corresponding reduction in
infarct scar (5.1  0.5 mm to 3.6  0.2 mm, p  0.044). No changes occurred in control
subjects (n  4). Tagging MRI demonstrated time-dependent recovery of active contractility
paralleling new tissue appearance. This rim was composed of morphologically normal
cardiomyocytes, which were smaller in MSC-treated versus control subjects (11.6  0.2 m
vs. 12.6  0.2 m, p  0.05).
CONCLUSIONS With serially obtained MRI and MDCT, we demonstrate in vivo reappearance of myocardial
tissue in the MI zone accompanied by time-dependent restoration of contractile function.
These data are consistent with a regenerative process, highlight the value of noninvasive
multimodality imaging to assess the structural and functional basis for myocardial regener-
ative strategies, and have potential clinical applications. (J Am Coll Cardiol 2006;48:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.06.0732116–24) © 2006 by the American College of Cardiology Foundation
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dschemic cardiomyopathy due to myocardial infarction (MI)
s the major cause of congestive heart failure and death in
he Western world (1). There is accumulating experimental
upport for the application of cellular transplantation as a
trategy to improve myocardial function (2–8) and reduce
car burden due to MI (2–4,8); however, controversy exists
egarding the underlying mechanism(s) for this effect. In
articular, the question of whether transplanted cells regen-
rate new myocardium (either through differentiation or
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niversity School of Medicine, Baltimore, Maryland; †Institute for Cell Engineering
ICE), Johns Hopkins University School of Medicine, Baltimore, Maryland; and
OsirisTherapeutics, Baltimore, Maryland. This work was supported by the Johns
opkins University School of Medicine Institute for Cell Engineering (ICE);
ational Institutes of Health grants U54 HL081028 (Specialized Center for
ell-Based Therapy), R21 HL-72185 and RO1 NIA AG025017; and the Donald
. Reynolds foundation. Dr. Hare has received research grant funding from Osiris
herapeutics.t
Manuscript received February 27, 2006; revised manuscript received June 6, 2006,
ccepted June 29, 2006.ell–cell signaling to endogenous precursor cells) to replace
hose lost to MI (9,10) remains unanswered. Additionally,
he use of different cell populations and varying clinical
rotocols and their application in diverse patient groups has
ampered any effort to compare outcomes using the various
ell types with one another (11).
Critical in assessing the efficacy of any novel regenerative
herapy is the ability to noninvasively image tissues within
he heart at various time points. Moreover, it is essential to
etermine whether regenerated tissue is functional (i.e.,
oes the new tissue contract with the rest of the heart or is
t non-contractile and mechanically uncoupled from the rest
f the heart), in which case it might actually be detrimental
o cardiac function.
Implantation of cells such as bone marrow-derived mes-
nchymal stem cells (MSC) restores the function of the
amaged heart and decrease necrotic tissue (8,12). Whether
hey do so by generating new, electromechanically coupled
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volving scar, thereby preventing remodeling (15,16), re-
ains controversial. Some groups advocate that implanted
ells are not contractile but rather that new viable tissue
erves to decrease myocardial wall tension at the infarcted
egion by strengthening the infarct scar and preventing
entricular dilatation and thus improving diastolic function
nd enhancing global cardiac function (16,17). Others
uggest there is actual regeneration of functional myocar-
ium that replaces the area occupied by scar (3). Whether
his occurs by (trans)differentiation of the implanted cells
nto new cardiomyocytes, whether there is fusion of the
onor cells with the surviving cells inducing cellular turn-
ver, or whether the injected cells stimulate endogenous
yocytes or myocyte precursors to divide via a paracrine or
ell–cell signaling action is incompletely understood.
To address this important issue we used multimodality
maging, with both magnetic resonance imaging (MRI) and
ontrast-enhanced multi-detector computerized tomogra-
hy (MDCT) to serially monitor the regional and global
tructure and function of the porcine heart after MI in
esponse to allogeneic MSC therapy. We have previously
emonstrated that MSC therapy leads to the development
f a sub-endocardial rim of muscle and improvement in
verall cardiac function (12); however, whether this rim of
yocardium is functionally coupled to the rest of the heart
emains unknown. We therefore tested the hypothesis that
SC cellular cardiomyoplasty stimulates the regeneration
f viable, contractile myocardium adjacent to evolving MI
car thereby enhancing regional systolic function.
ETHODS
xperimental protocol. All animal studies were approved
y the Johns Hopkins University School of Medicine
nstitutional Animal Care and Use Committee and comply
ith the “Guide for the Care and Use of Laboratory
nimals” (National Institutes of Health [NIH] Publication
o. 80-23, revised 1985). Twenty-three female Yorkshire
igs (25 to 30 kg) underwent left anterior descending
oronary artery occlusion followed by reperfusion and then
ere randomized to receive MSCs (n  10) or not receive
SCs (n  12, non-treated group) 3 days later. Mortality
as not different between groups. In the control group,
Abbreviations and Acronyms
Ecc  systolic circumferential strain
FOV  field of view
LV  left ventricle/ventricular
MDCT  multi-detector computed tomography
MI  myocardial infarction
MMP  matrix metalloproteinase
MRI  magnetic resonance imaging
MSC  mesenchymal stem cell
TIMP  tissue inhibitor of matrix metalloproteinaseanimals died within 72 hours of MI and 3 animals died turing the follow-up period, resulting in 7 animals being
vailable for the imaging and histology protocols. In the
SC-treated group, 1 animal died after cell injection and
animals died during the follow-up period, resulting in
animals that were available for imaging and pathology
xaminations. Cine and tagging MRI assessment was per-
ormed at 4 time points after injection: 2 days and 1, 4, and 8
eeks. Also, MDCT was performed at 1 week and 8 weeks
fter MI. Detailed protocols are in the following sections.
artial data—ejection fraction and infarct size obtained from
RI, and histologically measured rim thickness—from a
ubset (n  6 MSC and n  6 control subjects) of these
nimals have previously been reported (12).
I creation and intramyocardial MSC injection. The
rotocol used here has been previously described (12). In brief,
ntravascular sheaths were placed in the right carotid artery
8-F), and a coronary angioplasty balloon (2.5  20 mm)
as advanced into the proximal left anterior descending
oronary artery. Myocardial infarction was induced by
nflating the angioplasty balloon for 60 min, followed by
rtery reperfusion. After reperfusion, the catheter sheath in
he carotid artery was removed, and the carotid artery was
ermanently closed. All animals were adequately heparin-
zed during the surgical procedure.
Three days after MI, animals randomized for MSC treat-
ent received intramyocardial injections of allogeneic porcine
SCs (2.0  108 cells, Osiris Therapeutics, Baltimore,
aryland) under fluoroscopy, with a pistol-needle tip in-
ection catheter advanced to the LV through a steerable
uide catheter (Stiletto, Boston Scientific, Natick, Massa-
husetts).
Hypokinetic, akinetic, and dyskinetic areas were identi-
ed during contrast ventriculography, and MSC injections
ere performed within and at the borders of the dysfunc-
ional area, as defined by bi-plane ventriculography. A total
f 15 injections were performed in each animal, each
njection containing 1 cc, thereby delivering a total of
00 million cells/animal. Each injection was fluoroscopi-
ally guided to distribute cells evenly throughout the entire
nfarct and border zones.
RI protocol. The MRI images were acquired with a 1.5-T
R scanner (CV/i, GE Medical Systems, Waukesha, Wis-
onsin) at 4 time points after injection: 2 days and 1, 4, and
weeks. Global LV function was assessed with a steady-
tate free precession pulse sequence (18). Eight to 10
ontiguous short-axis slices were prescribed to cover the
ntire heart from base to apex. Image parameters were the
ollowing: repetition time (TR)  4.2 ms and echo time
TE)  1.9 ms; flip angle  45°; 256  160 matrix; 8-mm
lice thickness/no gap; 125 kHz; 28-cm field of view
FOV); and 1 number of signal average (NSA).
To assess regional cardiac function, tagging MRI images
ere acquired with an electrocardiography-gated, seg-
ented K-space, fast gradient recalled echo pulse sequence
ith spatial modulation of magnetization to generate a gridag pattern (19,20). Images were obtained at the same
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Multimodality Imaging of MSC Therapy After MI November 21, 2006:2116–24ocation as the cine-MRI images, and image parameters
ere as follows: TR 6.7 ms and TE 3.2 ms; flip angle
2°; 256  160 matrix; views/s: 4; 8-mm slice thickness/no
ap; 31.25 kHz; 28-cm FOV; 1 NSA; and 6 pixels tagging
pace.
RI analysis. Cine-MRI images were analyzed with a
ustom research software package (Cine Tool, GE Medical
ystems). Endocardial and epicardial contours were done
anually at end-diastolic and end-systolic phases of the
ardiac cycle, and global cardiac function was assessed on
he basis of Simpson’s rule method.
The high resolution of current generation MRI scanners
llows differential assessment of contractile function at
arious levels within the myocardium at any given circum-
erential point. We assessed contraction in 24 circumferen-
ial areas of the LV, and in each of theses areas we assessed
ontractile function from 3 different layers of the myocardial
all: endocardial, mid-myocardial, and epicardial layers.
agged images were quantitatively analyzed with a custom
oftware package (Diagnosoft HARP, Diagnosoft Inc., Palo
lto, California) (21). Regional strain magnitude was de-
ermined from the 24 radially displaced segments for each
hort-axis section covering the entire LV and averaged
mong slices for each region and each time point, as
reviously described (22), generating a strain map for each
oint over the cardiac cycle. The peak systolic circumferen-
ial strain (Ecc) was determined from the strain map for
ach point. This approach is most similar to many com-
only used indexes based on tissue Doppler functional
maging. Negative Ecc values represent myocardial contrac-
ion, whereas values of increasing strain (toward positive
alues) reflect worsening contractile function in that region.
ess negative Ecc values represent hypokinetic myocar-
ium. A value of 0 represents akinetic non-contractile
yocardium, and a positive value represents dyskinetic
yocardial segments. Peak systolic circumferential strain
peak Ecc) was calculated for each layer as previous de-
cribed (21). Also, peak Ecc was separated from infarcted
nd non-infarcted (remote) areas for each animal.
DCT imaging protocol. The MDCT images were ob-
ained in the first week after MI (baseline) and 8 weeks after
SC injection in a subset of animals (n  4 in each group)
ith a 32-detector scanner (Aquilion 32 Toshiba Medical
ystems Corporation, Otawara, Japan). The specific proto-
ol used has been previously described and validated by
ardo et al. (23). In brief, a stack of axial slices (0.5-mm
lice thickness) was prescribed to cover the entire heart.
mages were acquired 5 min after contrast injection (iodixa-
ol 150 ml, 5 cc/s), the ideal time for infarct visualization.
maging acquisition parameters were as follows: gantry rotation
ime 400 ms; detector collimation 0.5 mm 32; pitch
.2; tube voltage  135 kV; tube current  420 mAs; and
canning FOV  13.2 mm.
DCT imaging analysis. Axial images were recon-
tructed at 75% of the cardiac cycle and at 2-mm slice
hickness. Image analysis was performed with a custom tesearch software package (Cine Tool, GE Medical Sys-
ems), and areas of necrosis were identified as hyper-
nhanced areas. The multi-detector slice CT technique was
hosen owing to its high spatial resolution and ability to
void the partial volume effect, allowing for better charac-
erization of scar region (24). In the infarct zone, thickness
easurements of the entire infarct zone, the scar, and the
ndocardial rim were made at 4 points in each slice and
slices for each animal, and the average was taken.
tem cell harvest and isolation. Male swine MSCs (Osiris
herapeutics) were obtained, isolated, and expanded as
reviously described (12,25). All used cells were harvested
hen they reached 80% to 90% confluence at passage 3, and
hen cells were placed in cryo bags at a concentration of 10
o 15 million MSCs/ml and frozen in a control rate freezer
o 180°C until the day of implantation. Trypan blue
taining was performed to attest viability of thawed MSC
ots before injection. Only MSC lots containing 85% or
ore of viable cells were used in the study.
ostmortem analysis. Quantification of viable myocar-
ium in the subendocardial border of the MI was confirmed
y gross pathology. For this purpose, at the end of the
-week period, animals were humanely killed and hearts
ere excised and sectioned into 8-mm-thick short-axis
lices. Each slice was digitally photographed. For each slice,
on-viable infarcted areas and viable subendocardial border
hickness were manually measured with a custom research
oftware package (Image J 1.34s; NIH, Bethesda, Maryland),
nd an average of 6 measurements were taken for each
pecimen that was used. The amount of viable sub-
ndocardial tissue is expressed in absolute terms and as a
atio of viable tissue (mm width) normalized by infarct
ransmurality (mm width) of each slice. The sub-
ndocardial rim thickness data from a subset of these
nimals have previously been reported (12). The LV cir-
umference was measured at the endocardium and epicar-
ium, as was the circumference of the infarct zone, and the
nfarct zone was expressed as the percentage of the LV
ircumference average of the endocardial and epicardial
easurements.
After photographs were taken, myocardial tissue samples
ere obtained from 2 regions: infarcted and remote (nor-
al) areas. Hematoxylin and eosin (H&E) stain was per-
ormed, and myocyte length was measured from the remote
nd infarcted areas (viable tissue at subendocardial border),
ith a custom research software package (Scion Image
nalysis program; Beta version 4.0.2; Scion Corporation,
rederick, Maryland). One hundred myocytes were measured
t each site from 2 control and 2 MSC animals with similar
nitial infarct size and morphology.
tatistical analysis. All values are expressed as mean 
EM. Indexes of cardiac function as well as amount of
iable tissue at day 2 and week 8 were compared between
roups with non-paired independent samples Student t test.
he change in sub-endocardial rim thickness and scarhickness within groups from baseline to 8 weeks were
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November 21, 2006:2116–24 Multimodality Imaging of MSC Therapy After MInalyzed with a paired Student t test. Differences in ejection
raction and infarct size during the 8-week period were
ompared within the groups with repeated measurements
nalysis of variance (ANOVA) and between groups with
-way ANOVA with an interaction term. Simple linear
egression analysis was performed to compare peak Ecc
etween groups at different time points, and the Huber/
hite Sandwich estimator of variance was used to take
orrelation between the animals into account. A level of p
.05 was considered statistically significant.
ESULTS
erial imaging demonstrates reappearance of myocardial
issue. There were no baseline differences between groups
Table 1). We examined the tissue characteristics of the
nfarcted regions in vivo with high definition MDCT
maging at several time points and compared this with
istological analysis. The CT images offered important
etails regarding changing scar morphology and tissue
haracteristics due to MSC treatment. The MDCT images
n the first week after MI (Fig. 1) demonstrated the
resence of a rim of tissue at the endocardial layer of the MI
car, which had a tissue density similar to remote myocar-
ium (130.9  31.6 Hounsfield units). This rim increased
able 1. Baseline Characteristics
Control MSC-Treated p Value
I size (% of LV volume)* 18.3  3.4 20.2  2.3 NS
VED mass* 48.2  2.9 56.7  4.7 NS
VEF (%)* 29.8  1.9 29.1  2.6 NS
I zone thickness (mm)† 6.2  0.3 6.3  0.6 NS
aseline characteristics were not different between groups. *Measured by cine
agnetic resonance imaging. †Measured by Multi-slice detector computed tomog-
aphy.
LVED  left ventricular end-diastolic; LVEF  left ventricular ejection fraction;
I  myocardial infarction; MSC  mesenchymal stem cell.
igure 1. Multi-detector computed tomography scan of a pig 1 week after
ub-endocardial rim of viable tissue are clearly apparent. The sub-endocardial ri
elative densities in Hounsfield units (HU) are also represented. MSC  mesenn thickness during an 8-week interval, consistent with the
evelopment of potentially viable myocardial tissue. Addi-
ionally, there was a distinct difference in tissue density
etween viable myocardium and the infarct scar (235.9 48.6
ounsfield units) and this viable sub-endocardial tissue.
mage-based quantification of this sub-endocardial region
ver 8 weeks revealed no change in the overall thickness of
he infarct zone but an increase in thickness of the viable
ub-endocardial tissue in the MSC-treated group, from
.02  0.16 mm to 2.02  0.28 mm (p  0.028, n  4).
here was a corresponding reduction in the thickness of the
car in this region from 5.1  0.5 mm to 3.6  0.2 mm
p  0.044, n  4) (Fig. 2). However, in the untreated
roup, the total infarct zone thickness, the scar thickness,
nd the rim thickness remained unchanged from week 1 to
eek 8 (p  NS, n  4).
The generation of a sub-endocardial rim of myocardium
as confirmed by pathologic analysis. The MSC-treated
nimals had a 2.9  0.4-mm sub-endocardial rim of tissue,
epresenting 35  3% of the wall thickness in the infarct
one (n  6). Untreated animals (n  7), however, had a
hinner sub-endocardial rim, 1.4  0.1 mm (p  0.02 vs.
SC group), accounting for 21  2% of the wall thickness
p  0.004 vs. MSC-treated) (Fig. 3). Additionally, volu-
etric analysis of the infarct scar in 2 animals from each
roup demonstrated that MSC injection significantly re-
uced the volume of myocardial infarct scar tissue over the
ourse of the study period (49.5  9.9% decrease in infarct
ize at 8 weeks after MI; p  0.05 vs. baseline), whereas no
hange in infarct size was observed in non-treated animals
p  0.05 vs. MSC-treated animals).
The circumferential extent of the infarcted zone was not
ifferent between groups (22  3% vs. 24  4% of the LV
ircumference in MSC-treated and untreated animals, re-
pectively, p  0.56). Thus, regeneration of the infarct zone
cardial infarction. The different tissue densities of the infarct scar and themyo
m has a density similar to the myocardium outside the infarct zone. The
chymal stem cell.
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Multimodality Imaging of MSC Therapy After MI November 21, 2006:2116–24as not due to regeneration from the border zone inward
nto the scar, but due to regeneration of the sub-endocardial
im. Histological analysis confirmed that this rim at the
ndocardial region of the infarct zone contained properly
ligned cardiac myocytes (Fig. 4A). These myocytes were
maller than normal, with myocyte width of 11.6  0.2 m
s. 12.6  0.2 m (p  0.05) (Fig. 4B) for cardiomyocytes
n the region remote from the infarct. This finding excludes
yocyte hypertrophy as a cause for the increase in sub-
ndocardial rim thickness and is consistent with myocardial
egeneration in this region (3,4,8,12).
egenerated myocardium has coordinated contraction.
ext we examined whether the reduction in infarct size and
ts replacement with new myocardium resulted in recovery
f contractile function in this region. For this purpose, we
sed MRI tagging to calculate peak Ecc. Representative
agged imaging with color mapping to demonstrate normal
nd abnormal contraction is shown in Figure 5.
As depicted in Figure 6, both groups of animals had
ypokinetic wall motion in the endocardial layers of the
nfarct zone at baseline, 5.5  0.3% and 5.5  0.5%,
espectively, for MSC-treated and non-treated groups (p 
S). However, whereas this area remained hypokinetic in
ontrol animals for the 8-week duration of the study, the
ubendocardial area of MSC-treated pigs where regenera-
ion of myocardium occurred began to increase peak nega-
ive strain by 4 weeks, followed by near-full peak Ecc
ecovery, comparable to that of remote or non-infarcted
yocardium, by 8 weeks after injection (peak Ecc at week 8:
11.8  0.9 vs. 5.1  0.5 in MSC-treated vs. control
ubjects, p  0.05).
The epicardial layer of myocardium exhibited a somewhat
ifferent course over the 8-week study period. As shown in
igure 2. Multi-detector computed tomography scan of the same mesench
C) after MSC injection. There is a time-dependent reduction in the thi
ub-endocardial rim of tissue over the 8-week follow-up.igure 6, a depressed regional function was observed in both rroups with peak Ecc 4.2  0.3% and 5.5  0.5% for
SC-treated and control groups, respectively (p  NS).
owever, improvement in cardiac function was observed in
oth groups by the end of the 8-week study period (9.4 
.3 and 6.8  0.9 in MSC-treated and control groups,
espectively; p  0.05 vs. baseline for both and p  NS
etween groups). This improvement in regional function is
xpected, because the region most likely contains viable
yocardium, as confirmed previously by histological analy-
is (26).
To complete the analysis of regional function of the
hole wall, we examined the temporal course of peak Ecc in
he mid-wall region. Interestingly, despite the improvement
bserved at the epicardial layer in the non-treated animals,
o improvement or movement gathering occurred in the
id-wall layer. Initial peak Ecc was depressed at 4.1 
.4% at baseline and did not improve in the course of the
weeks in the non-treated animals, with a peak Ecc of
4.7  0.6% (p  NS vs. baseline). However, MSC-
reated animals demonstrated an important improvement in
egional peak Ecc shortening at the mid-wall region, from
4.6  0.3% to 10.8  0.6%, leading to near normal
evels at 8 weeks after injection (p  0.05 vs. non-treated).
These data are consistent with restoration of contractile
unction in the endocardial and mid-wall areas of the
nfarcted myocardium in animals treated with MSC injec-
ion, not evident in untreated animals. It is important to
ote that the entire infarct zone of both groups remained
ypokinetic at the time of the week-1 MRI, demonstrating
hat the development of contractility in the MSC-treated
roup developed over several weeks. The timescale of
mprovement coupled with the CT findings of scar replace-
ent with myocardium in this area strongly suggests that
stem cell (MSC)-treated animal at 5 days (A), 4 weeks (B), and 8 weeks
s of the infarct scar and a corresponding increase in the thickness of theymalegeneration of functional myocardium rather than just
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November 21, 2006:2116–24 Multimodality Imaging of MSC Therapy After MIecovery of stunned myocardium is the mechanism of
ecovery.
egenerated myocardium improves global cardiac func-
ion. Enhancement of regional cardiac function in the
nfarct zone leads to improvement in global cardiac function
Fig. 7). As previously reported, the LV ejection fraction
mproved in a time-dependent manner in the MSC-treated
roup but not in the control group (12). Importantly, this
mprovement followed a time course similar to that of the
bserved myocardial regeneration and the improvement in
igure 3. (A) Multi-detector computed tomography scan of representative
he arrows, both infarct zones are characterized by the presence of a rim o
im progressively increases in mesenchymal stem cell (MSC)-treated anim
pecimens from control and MSC-treated animals confirm increased sub-egional contraction. aISCUSSION
ere we show that multimodality imaging with MRI and
DCT allows precise characterization of tissue mor-
hology and regional and sub-regional cardiac function
hat demonstrates the structural and functional response
o cell-based therapy in a large animal model. Together,
ur results demonstrate that transplantation of allogeneic
SCs in pigs 3 days after MI stimulates cardiac repair by
eading to the reappearance and/or growth of new tissue
cardial infarcts at weeks 1 and 8 after stem cell injection. As indicated by
cardial tissue on their endocardial surface. However, the thickness of this
nd remains unchanged in control subjects. (B) Representative pathology
ardial rim thickness in the treated animals.myo
f myo
als along the sub-endocardial rim of the MI that partially
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Multimodality Imaging of MSC Therapy After MI November 21, 2006:2116–24eplaces the infarct scar. This tissue is contractile and
echanically coupled with the existing myocardium,
emonstrating that cellular cardiomyoplasty with MSCs
igure 4. Hematoxylin and eosin (H&E) stain of tissue obtained from the
ubendocardial rim (A) and the remote zone (B) of mesenchymal stem cell
MSC)-treated animals. As shown, the rim of tissue is made up of cardiomy-
cytes with normal ultrastructural architecture. (C) There is no difference in
he size of myocytes taken from the remote myocardium of both control and
SC hearts. However, the myocytes from the infarct rim are significantly
maller in MSC-treated animals versus control animals (n  2 each, 100
ells/heart), suggesting that the enhanced rim size in MSC animals might be
ue to new cardiomyocyte regeneration. *p 0.001 MSC rim versus control rim.
igure 5. Color map depicting non-contractile and dysfunctional areas
emonstrates the spectrum in change of systolic cardiac function: blue
ysfunctional areas. Non-treated animals exhibited worsening regional systolic
oticed in the mesenchymal stem cell (MSC)-treated animals.ikely stimulates regeneration of myocytes as the basis for
he improvement in regional and global function and the
eduction in infarct size. Importantly, these insights were
leaned from imaging modalities that did not require
abeling of injected cells.
igure 6. Plot of peak circumferential strain (peak Ecc) over time com-
aring mesenchymal stem cell (MSC)-treated and non-treated animals for
myocardial layers (endocardial, epicardial, mid-wall layers). Peak negative
cc values represent myocardial shortening, whereas increasingly positive
alues reflect relative myocardial dysfunction. As can be appreciated, peak
egative Ecc values at the endocardial and mid-wall layers for MSC-
reated infarct regions decrease (i.e., improve) over the 8-week follow-up
eriod compared with the control group, which remained dysfunctional.
p  0.05 difference within the group; ‡p  0.05 difference between
roups; n  6 in each group. MI  myocardial infarction.
yocardium detected by tagging magnetic resonance imaging. Bar color
green colors identify normal contractile areas and red colors representof m
andfunction during the 8-week period, whereas a visual improvement was
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November 21, 2006:2116–24 Multimodality Imaging of MSC Therapy After MIThere is growing evidence that cellular cardiomyoplasty is
easible and capable of restoring global cardiac function
2–6,8,12,27). Studies using MSCs (8,12) and MSC-like
28) cells have demonstrated a beneficial effect in post-MI
earts, and these reports together have encouraged the
pplication of this novel therapy in phase I clinical trials.
owever, there is ongoing controversy regarding the mech-
nistic underpinnings by which stem cell therapy improves
ardiac function (11). There is strong evidence that MSCs
articipate in the regulation of collagen formation and that,
n so doing, alter the passive characteristics of the scar,
endering it less susceptible to stretch and contributing to
verall improvement in global chamber function. In this
egard, Xu et al. (29) have reported that MSCs in a rat
odel of MI positively influence the composition of extra-
ellular matrix at the scar, altering the expression of matrix
etalloproteinase (MMP-1) and tissue inhibitor of matrix
etalloproteinases (TIMPS), among other components.
thers have demonstrated improved ventricular compliance
fter MSC therapy and suggested that this, in concert with
educed scar formation, might contribute to the improve-
ents in LV function (17). Although the current study does
ot refute this mechanism, it strongly supports the notion
hat cardiac tissue reappears in an endomyocardial rim
orresponding to the location of cell administration. The
emonstration of a reduction in scar volume in concert with
he increase in myocardium in the infarct zone supports the
dea that effects on MMPs and TIMPs and myocyte
egeneration are both operative mechanisms.
echanistic basis for tissue regeneration. Evidence for
SC differentiation into myocytes remains controversial.
hereas in vitro observations support differentiation (30),
n vivo studies demonstrate incomplete differentiation with
SCs harboring myocyte-specific proteins but lacking full
ardiomyocyte phenotypes (12,31). Mesenchymal stem cells
re reported to produce cardiac connexin 43 (14) and could in
heory electromechanically couple to host myocardium (32).
The demonstration of smaller but seemingly mature
ardiomyocytes in the sub-endocardial rim of the infarct
igure 7. Impact of mesenchymal stem cell (MSC) therapy on global
entricular function. Ejection fraction assessed by cine magnetic resonance
maging (MRI). Ejection fraction is markedly reduced in both groups at
aseline and remains depressed in non-treated animals. However, a
rogressive improvement in the course of 8 weeks is observed in MSC-
reated animals. *p  0.05 versus day 2 after injection (time 0); †p  0.05
ersus non-treated (n  6).one confirms that the increase in tissue seen in this region cs not due to hypertrophy of the cardiomyocytes but rather
uggests growth of new tissue. It has previously been shown
hat the cardiomyocytes in this region are ki67 positive, also
uggesting growth of new tissue (12). However, whether
his occurs due to MSC differentiation into cardiomyocytes,
o proliferation of endogenous cardiomyocytes or their
recursors, or to other currently unappreciated mechanisms
emains to be determined. Studies aimed at elucidating the
elative contributions of these mechanisms are currently
ngoing.
There are other postulated potential mechanisms of
ction. First, MSCs likely stimulate homing of endogenous
recursor cells (33,34). Systemically injected MSCs home to
he site of tissue damage after MI (35,36), demonstrating
heir participation in cellular trafficking. Additionally,
SCs themselves secrete stromal derived factor 1 (SDF-1),
stem cell chemoattractant cytokine (37) and might there-
ore promote trafficking and/or differentiation of other stem
ells, such as endothelial progenitor cells (EPCs) or endog-
nous cardiac stem cells. It is attractive to speculate that
SCs might act as an amplifier to enhance the function of
ndogenous cardiac stem cells in effecting myocardial re-
eneration. Indeed, it has been shown that exogenous
ignals introduced after MI can cause proliferation and
ifferentiation of endogenous cardiac stem cells, resulting in
yocardial regeneration and improved LV function (38).
esenchymal stem cell transplantation might act in a
aracrine or cell–cell signaling fashion to effect cardiac
epair via cytokine-induced enhancement of endogenous
ardiac stem cell function.
Another proposed mechanisms for new tissue regenera-
ion is cell fusion (39) of the implanted MSCs with host
ells. However, fusion seems increasingly unlikely given the
ccumulation of abundant data revealing diploidy of regen-
rated cells (40–42). Our study has not specifically ad-
ressed the issue of how myocyte regeneration occurs, but
e have confirmed that it does occur, that it happens in a
ime-dependent manner, that it develops along the suben-
ocardial surface of the scar, and that it results in functional
ontractile improvement. Further studies are underway to
ore fully elucidate the mechanism by which MSC therapy
nduces myocardial regeneration.
In summary, we have used multimodality state-of-the-art
maging to serially follow the response of a large-animal
odel of MI to MSC cell therapy and demonstrate the
resence of myocardial regeneration over several time
oints. In addition, we demonstrate that this new tissue
nhances regional systolic function, which in turn leads to
n improvement in global chamber performance. These data
emonstrate the efficacy of intramyocardial MSC injection
fter MI and highlights the value of noninvasive multimo-
ality imaging not only in elucidating mechanisms under-
ying new tissue regenerative therapies but also in serially
ssessing these tissue changes and their functional conse-
uences. These results have implications for the design of
linical trials of stem cell therapy.
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